참고문헌
- Cao X, Zhang T, Zhao Z, et al (2012). MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis. DNA Cell Biol, 31, 355-9. https://doi.org/10.1089/dna.2011.1338
- Fang Z, Chen F, Wang X, et al (2013). XRCC1 Arg194Trp and Arg280His polymorphisms increase bladder cancer risk in Asian population: evidence from a meta-analysis. PLoS One, 8, e64001. https://doi.org/10.1371/journal.pone.0064001
- Gangwar R, Mittal RD (2010). Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol, 29, 349-56. https://doi.org/10.1089/dna.2009.0982
- GLOBOCAN 2012, IARC. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
- Greenblatt MS, Bennett WP, Hollstein M, et al (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 54, 4855-78.
- Hitzenbichler F, Stoehr CG, Rogenhofer M, et al (2014). Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer. Pathobiology, 81, 53-9. https://doi.org/10.1159/000355976
- Horikawa Y, Nadaoka J, Saito M, et al (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep, 20, 49-55.
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Knowles MA (2008). Molecular pathogenesis of bladder cancer. Int J Clin Oncol, 13, 287-97. https://doi.org/10.1007/s10147-008-0812-0
- Kubbutat MH, Jones SN, Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature, 387, 299-303. https://doi.org/10.1038/387299a0
- Levine AJ, Momand J, Finlay CA (1991). The p53 tumour suppressor gene. Nature, 351, 453-6. https://doi.org/10.1038/351453a0
- Ma HB, Huang T, Han F, et al (2012). Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6. https://doi.org/10.7314/APJCP.2012.13.6.2841
- Ma Y, Bian J, Cao H (2013). MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PloS One, 8, 56918. https://doi.org/10.1371/journal.pone.0056918
- McConkey DJ, Lee S, Choi W, et al (2010). Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol, 28, 429-40. https://doi.org/10.1016/j.urolonc.2010.04.008
- Mommsen S, Aagaard J (1983). Tobacco as a risk factor in bladder cancer. Carcinogenesis, 4, 335-8. https://doi.org/10.1093/carcin/4.3.335
- Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, et al (2007). Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol, 25, 285-95. https://doi.org/10.1007/s00345-007-0168-5
- Olfert SM, Felknor SA, Delclos GL (2006). An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J, 99, 1256-63. https://doi.org/10.1097/01.smj.0000247266.10393.72
- Onat OE, Tez M, Ozcelik T, et al (2006). MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res, 26, 3473-5.
- Pietsch EC, Humbey O, Murphy ME (2006). Polymorphisms in the p53 pathway. Oncogene, 25, 1602-11. https://doi.org/10.1038/sj.onc.1209367
- Tian X, Tian Y, Ma P, et al (2013). Association between MDM2 SNP309 T>G and risk of gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 1925-9. https://doi.org/10.7314/APJCP.2013.14.3.1925
- Wang L, Liu Z, Jing P, et al (2014). Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol, 35, 1649-52. https://doi.org/10.1007/s13277-013-1227-8
- Wang LH, Wang X, Xu WT, et al (2014). MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis. Tumour Biol, 35, 3167-70. https://doi.org/10.1007/s13277-013-1413-8
- Wang M, Zhang Z, Zhu H, et al (2008). A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res, 14, 3633-40. https://doi.org/10.1158/1078-0432.CCR-07-5155
- Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107. https://doi.org/10.1038/nrc2584
- Zhao E, Cui D, Yuan L, et al (2012). MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep, 39, 3471-7. https://doi.org/10.1007/s11033-011-1119-1